查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015090

腫瘤營養市場：依產品類型、給藥途徑及通路分類－2026-2032年全球市場預測

Oncology Nutrition Market by Product Type, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症營養市場價值將達到 29.9 億美元，到 2026 年將成長到 32.2 億美元，到 2032 年將達到 52 億美元，複合年成長率為 8.22%。

主要市場統計數據
基準年 2025 29.9億美元
預計年份：2026年 32.2億美元
預測年份 2032 52億美元
複合年成長率 (%) 8.22%

本文將重點介紹營養策略在癌症治療中不斷變化的作用，以及為什麼綜合方法對臨床和商業相關人員。

腫瘤營養日益被認為是綜合癌症治療的關鍵要素，它影響著患者的治療耐受性、復原過程和整體預後。在現代醫療環境中，臨床營養科學的進步與不斷發展的醫療服務模式正在融合，為臨床醫生、營養師和相關人員創造了新的溝通管道。營養管理如今與精準癌症治療、支持性治療方案和以價值為導向的醫療保健舉措緊密結合，使得營養策略成為多學科癌症診療計畫不可或缺的一部分。

臨床創新、產品特性和不斷發展的醫療保健服務模式如何重塑癌症營養的實踐和商業性重點。

癌症營養領域正經歷一場變革，其驅動力來自臨床實踐的進步、以患者為中心的護理理念的提升以及供應鏈的重組。如今，臨床路徑強調早期營養篩檢和積極干預，這使得經腸營養和口服製劑在手術全期和支持性治療中的作用日益凸顯。這種以預防和最佳化為重點的臨床實踐正在重塑醫院和專科診所的採購模式，並促進癌症治療團隊與營養專家之間更緊密的合作。

本研究分析了 2025 年美國的收費系統將如何影響供應鏈的韌性、採購選擇以及癌症營養照護的連續性。

2025年美國全面實施的關稅調整為腫瘤營養領域的企業帶來了一系列複雜的營運和採購挑戰。供應鏈經理和採購人員被迫重新評估籌資策略，審查與供應商的關係，並檢驗物流網路的韌性。因此，製造商和經銷商面臨最佳化生產基地、降低成本的壓力，同時也確保產品品質和合規性。

基於細分市場的詳細洞察，將產品配方、給藥途徑和分銷管道特徵與臨床和商業性重點相結合。

細分市場洞察揭示了產品配方、給藥途徑和通路方面存在的細微機會和差異化需求。根據產品類型，市場細分為三大類：經腸營養、口服營養補充品和腸外營養。經腸營養又進一步細分為元素營養、模組化營養和標準營養，分別針對不同的消化耐受性和臨床適應症。元素營養適用於嚴重吸收不良或嚴重黏膜損傷的患者；模組化營養可根據臨床營養方案提供客製化的宏量營養素；標準營養則提供廣泛適用於手術全期和慢性病護理的營養支持。

區域比較觀點突顯了臨床實踐、報銷制度和分銷基礎設施如何影響世界各地市場的癌症營養策略。

癌症營養領域的區域趨勢反映了醫療服務模式、報銷機制和臨床實踐模式的差異。在美洲，綜合醫院系統和專科癌症中心強調多學科診療方案和早期營養干預，同時居家營養服務和遠距遠端醫療監測也日益普及。該地區的供應鏈能力支持多元化的分銷管道，相關人員也越來越重視與支付方的合作以及將營養干預納入臨床路徑，以促進特製配方的引入。

本文展示了一家公司透過產品創新、臨床支援服務和強大的分銷模式來重塑其競爭地位的策略方法。

癌症營養領域的主要企業透過整合配方創新、臨床專案支援和供應鏈最佳化來脫穎而出。領先的製造商正投資於涵蓋元素經腸營養營養、疾病特異性口服補充劑、高蛋白產品和綜合腸外營養產品線的產品系列組合，使臨床醫生能夠選擇滿足癌症患者複雜需求的治療方法。這些公司還優先考慮其腸外營養產品的安全性和相容性，以降低靜脈注射期間感染和代謝併發症的風險。

為相關人員提供可操作的建議，將證據產生、供應鏈韌性和有針對性的商業化結合起來，以改善癌症營養護理的結果。

行業領導企業應採取協作策略，將臨床證據、卓越營運和相關人員參與相結合，以推進以患者為中心的營養護理。首先，應投資建立健全的臨床證據項目，該項目不僅包括隨機對照試驗，還應涵蓋可操作的真實世界研究和病患報告結局指標。這些數據將揭示特定配方和給藥途徑對治療耐受性和復原的影響，同時加強與臨床醫生、保險公司和指南制定者的關係。

透過結合臨床文獻、專家訪談和營運分析主導調查方法，我們為癌症營養領域的相關人員提供了切實可行的見解。

本研究整合了同行評審的臨床文獻、監管指南、相關人員訪談和實踐評估，旨在全面了解癌症營養護理的實踐和商業性趨勢。臨床見解來自指引出版刊物、共識聲明以及近期針對癌症病患營養介入的臨床試驗，重點在於圍手術全期照護、惡病質管理和支持性照護方案。來自執業註冊營養師、腫瘤科醫生、醫院藥劑師和專科診所管理人員的意見，為了解與實際臨床工作流程、藥物選擇決策和患者用藥依從性相關的挑戰提供了背景資訊。

簡明扼要的結論強調了個人化營養策略在癌症治療中的關鍵作用，以及相關人員之間協調實施的必要性。

總之，在藥物科學、醫療服務模式和實證醫學證據累積的推動下，腫瘤營養管理正從輔助支持轉變為多學科癌症治療的核心要素。臨床醫生擴大採用預防性營養篩檢和個人化干預措施，涵蓋經腸營養、口服和靜脈營養途徑，這影響著採購、分銷和商業化策略。臨床特徵、通路和區域醫療保健系統的相互作用要求我們採取適應性強的方法，優先考慮實證實施和營運連續性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：腫瘤營養市場：依產品類型分類

  • 經腸營養
    • 基本營養素
    • 模數公式
    • 標準配方
  • 口服營養補充品
    • 疾病特異性類型
    • 高蛋白
    • 免疫營養
  • 腸外營養
    • 支持性腸外營養
    • 全靜脈營養

第9章：腫瘤營養市場：依給藥途徑分類

  • 經腸營養
  • 口服
  • 腸外

第10章 腫瘤營養品市場：依通路分類

  • 醫院藥房
  • 線上零售
  • 零售藥房
  • 專科診所

第11章 腫瘤營養市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 腫瘤營養市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 腫瘤營養市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國腫瘤營養市場

第15章：中國腫瘤營養市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Ajinomoto Co., Inc.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Danone SA
  • Fresenius SE & Co. KGaA
  • Hormel Foods Corporation
  • Koninklijke DSM NV
  • Meiji Holdings Co., Ltd.
  • Nestle SA
  • Reckitt Benckiser Group plc
Product Code: MRR-036C5CF3A8D2

The Oncology Nutrition Market was valued at USD 2.99 billion in 2025 and is projected to grow to USD 3.22 billion in 2026, with a CAGR of 8.22%, reaching USD 5.20 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.99 billion
Estimated Year [2026] USD 3.22 billion
Forecast Year [2032] USD 5.20 billion
CAGR (%) 8.22%

A focused introduction on the evolving role of nutritional strategies in oncology care and why integrated approaches matter for clinical and commercial stakeholders

Oncology nutrition is increasingly recognized as a pivotal component of comprehensive cancer care, influencing treatment tolerance, recovery trajectories, and overall patient outcomes. The contemporary landscape blends advances in clinical nutrition science with evolving care delivery models, generating new touchpoints for clinicians, dietitians, and commercial stakeholders alike. Nutritional management now intersects with precision oncology, supportive care protocols, and value-based care initiatives, making nutrition strategies essential to multidisciplinary cancer programs.

As therapies become more targeted and survivorship grows, nutritional needs shift in complexity and duration. This requires coordinated approaches that integrate enteral, oral, and parenteral modalities with individualized clinical plans. Clinicians must balance macronutrient and micronutrient requirements against treatment-related side effects such as mucositis, cachexia, nausea, and gastrointestinal dysmotility. Consequently, nutrition pathways extend beyond acute inpatient settings into outpatient and community care, emphasizing continuity, monitoring, and timely intervention.

From a commercial perspective, these clinical dynamics create demand for differentiated product portfolios, clinician education, and distribution frameworks that ensure access and adherence across diverse care settings. Strategic investments in evidence generation, stakeholder engagement, and formulary positioning will increasingly determine which products are adopted across multidisciplinary teams and care pathways.

How clinical innovations, product specificity, and evolving care delivery models are reshaping oncology nutrition practice and commercial priorities

The oncology nutrition landscape is undergoing transformative shifts driven by advances in clinical practice, patient-centered care expectations, and supply chain reconfiguration. Clinical pathways now emphasize early nutritional screening and proactive interventions, which has elevated the role of specialized enteral and oral formulations in perioperative and supportive care. This clinical emphasis on prevention and optimization has reshaped purchasing patterns in hospitals and specialty clinics, and has prompted greater collaboration between oncology teams and nutrition specialists.

Simultaneously, product innovation is moving toward formulation specificity and functional outcomes, with greater emphasis on high-protein solutions, immunonutrition components, and disease-adapted nutrient profiles. Innovations in parenteral nutrition management are also focusing on safety, infection control, and compatibility with increasingly complex pharmacotherapies. These product-level shifts are occurring alongside enhancements in patient-facing services such as home nutrition support, remote monitoring, and integrated care platforms that support adherence and symptom management.

Regulatory and payer environments are evolving in parallel, requiring clearer evidence on clinical benefit and cost-effectiveness. As a result, manufacturers and providers are prioritizing real-world evidence generation and value demonstration. These converging trends are transforming how clinicians select nutritional interventions and how organizations design programs that deliver measurable improvements in treatment tolerance and patient quality of life.

Analyzing how the 2025 tariff environment in the United States has affected supply chain resilience, procurement choices, and continuity of oncology nutrition care

The introduction of broad tariff changes in 2025 across the United States has introduced a complex set of operational and procurement considerations for organizations involved in oncology nutrition. Supply chain managers and procurement leaders have had to re-evaluate sourcing strategies, reassess supplier relationships, and examine the resilience of logistic networks. In turn, manufacturers and distributors faced pressure to optimize production footprints and mitigate cost pressures without compromising quality or regulatory compliance.

These tariff shifts reverberate through distribution networks spanning hospital pharmacies, retail chains, specialty clinics, and online channels. For products that rely on imported raw materials or finished goods, organizations pursued diversified sourcing and nearshoring strategies to reduce exposure to trade policy volatility. Simultaneously, there was an increased focus on inventory planning, lead-time buffering, and collaborative forecasting with suppliers to manage continuity of care for patients dependent on enteral, oral, or parenteral nutrition.

Clinicians and program managers experienced downstream effects as formulary decisions and procurement cycles adjusted to maintain access to clinically preferred formulations. In response, stakeholders have emphasized transparent communication across pharmacy, clinical, and supply chain functions to preserve therapeutic options and minimize disruption to patient care. Overall, the tariff environment reinforced the importance of supply chain agility, cross-functional coordination, and proactive scenario planning across the oncology nutrition ecosystem.

Deep segmentation-driven insights that align product formulation, administration route, and distribution channel characteristics with clinical and commercial priorities

Segment-level insights reveal nuanced opportunities and differentiated needs across product formulations, administration routes, and distribution pathways. Based on Product Type, the market is studied across Enteral Nutrition, Oral Nutritional Supplements, and Parenteral Nutrition. Enteral Nutrition is further differentiated into elemental formulas, modular formulas, and standard formulas, each catering to distinct digestive tolerances and clinical indications. Elemental formulations serve patients with significant malabsorption or severe mucosal compromise, modular formulas support customization of macronutrients in conjunction with clinical nutrition plans, and standard formulas offer broadly applicable nutrition support for perioperative and chronic care contexts.

Oral Nutritional Supplements are categorized across disease specific formulations, high protein preparations, and immunonutrition. Disease specific supplements are tailored to symptom clusters and metabolic profiles commonly seen in oncology patients, while high protein options address catabolic states and muscle preservation. Immunonutrition products incorporate targeted macro- and micronutrients designed to modulate inflammatory responses and support immune competence during treatment. Parenteral Nutrition is distinguished between supplemental parenteral nutrition and total parenteral nutrition, highlighting differing clinical thresholds for intravenous support and the complexity of central line management and metabolic monitoring.

Based on Route Of Administration, the market is studied across enteral, oral, and parenteral modalities, each presenting unique clinical workflows, monitoring needs, and patient education requirements. Based on Distribution Channel, the market is studied across hospital pharmacies, online retail, retail pharmacies, and specialty clinics, which together shape how products are accessed, reimbursed, and integrated into care teams. These segmentation perspectives underscore that successful strategies must align product design, evidence generation, and distribution tactics with the specific clinical contexts they are intended to serve.

Comparative regional perspectives highlighting how clinical practice, reimbursement frameworks, and distribution infrastructures influence oncology nutrition strategies across global markets

Regional dynamics in oncology nutrition reflect differences in healthcare delivery models, reimbursement practices, and clinical practice patterns. In the Americas, integrated hospital systems and specialty cancer centers emphasize multidisciplinary protocols and early nutrition intervention, with growing adoption of home-based nutrition services and telehealth-enhanced monitoring. Supply chain capabilities in the region support a variety of distribution channels, and stakeholders are increasingly focused on payer engagement and clinical pathway integration to facilitate adoption of specialized formulations.

Europe, Middle East & Africa presents a heterogeneous landscape where national health systems, regulatory frameworks, and resource constraints shape adoption. In several European markets, strong clinical guidelines and hospital-based formularies drive the use of evidence-backed nutrition interventions, whereas in parts of the Middle East and Africa, access challenges and logistics can limit availability to tertiary care centers. Across this combined region, partnerships between manufacturers and healthcare providers frequently focus on training, protocol development, and capacity building to extend nutrition support into broader oncology care pathways.

Asia-Pacific features rapid expansion of oncology services, an increasing emphasis on outpatient and home care models, and significant variability in private versus public payer structures. Local manufacturing and regional distribution networks play a central role in maintaining supply continuity, and there is growing interest in product innovations that address culturally specific dietary patterns and long-term survivorship needs. Together, these regional contrasts necessitate tailored go-to-market approaches that reflect payer dynamics, clinical infrastructure, and patient journey variations.

Strategic corporate approaches showing how product innovation, clinical support services, and resilient distribution models are reshaping competitive positioning

Key companies in the oncology nutrition space are differentiating through a combination of formulation innovation, clinical program support, and supply chain optimization. Leading manufacturers are investing in product portfolios that span elemental enteral solutions, disease specific oral supplements, high-protein options, and robust parenteral nutrition offerings, enabling clinicians to select therapies that match the complex needs of oncology patients. These companies are also prioritizing safety and compatibility features for parenteral products to reduce infection risks and metabolic complications during intravenous administration.

Beyond product lines, several firms are expanding services that include clinician education, patient adherence programs, and digital monitoring tools to support long-term nutrition management. Partnerships with hospital systems and specialty clinics facilitate protocol adoption and real-world evidence collection that strengthens clinical credibility. On the distribution side, companies are optimizing logistics through regional manufacturing strategies, strategic distributor relationships, and expanded online retail capabilities to ensure consistent access across hospitals, pharmacies, and home care settings.

Competitive differentiation increasingly hinges on the ability to demonstrate clinical value, offer integrated support services, and maintain resilient supply chains. Organizations that align product innovation with practical implementation support and evidence generation are better positioned to influence clinical pathways and secure long-term programmatic adoption.

Actionable recommendations for stakeholders to combine evidence generation, supply chain resilience, and targeted commercialization to enhance oncology nutrition outcomes

Industry leaders should pursue coordinated strategies that bridge clinical evidence, operational excellence, and stakeholder engagement to advance patient-centered nutrition care. First, invest in robust clinical evidence programs that extend beyond randomized trials into pragmatic real-world studies and patient-reported outcome measures; these data will strengthen relationships with clinicians, payers, and guideline developers while clarifying the impact of specific formulations and administration routes on treatment tolerance and recovery.

Second, fortify supply chain resilience by diversifying sourcing, optimizing regional production capabilities, and integrating collaborative forecasting with major health system customers. This approach reduces exposure to trade policy fluctuations and helps ensure continuity of clinically preferred products. Third, tailor go-to-market strategies by aligning product portfolios with the needs of hospital pharmacies, retail and online channels, and specialty clinics, while offering educational programs and digital adherence tools that support clinicians and patients across care transitions.

Finally, engage proactively with payers and policymakers to articulate value propositions that encompass clinical outcomes, patient quality of life, and system-level efficiencies. By combining evidence generation, operational robustness, and stakeholder-centric commercialization, leaders can accelerate adoption of nutrition interventions that materially improve oncology care delivery.

An evidence-driven methodology combining clinical literature, expert interviews, and operational analysis to produce actionable insights for oncology nutrition stakeholders

This research synthesizes peer-reviewed clinical literature, regulatory guidance, stakeholder interviews, and operational assessments to construct a comprehensive view of oncology nutrition practice and commercial dynamics. Clinical insights were drawn from guideline publications, consensus statements, and recent trials focused on nutritional interventions in oncology populations, with attention to perioperative care, cachexia management, and supportive care protocols. Input from practicing dietitians, oncologists, hospital pharmacists, and specialty clinic managers provided context on real-world workflows, formulary decision-making, and patient adherence challenges.

Operational and commercial perspectives were informed by supply chain assessments, distribution channel analyses, and structured interviews with procurement leaders and distributors. These sources were integrated through thematic synthesis, triangulating clinical evidence with supply chain realities and payer considerations to generate actionable insights. Throughout the process, emphasis was placed on the practical implications of segmentation across product types, routes of administration, and distribution channels, and on regional nuances that affect implementation. Insights were validated through expert review to ensure relevance and applicability to decision-makers focused on improving nutrition support in oncology settings.

A concise conclusion emphasizing the integral role of tailored nutritional strategies in oncology care and the need for coordinated implementation across stakeholders

In conclusion, oncology nutrition is transitioning from a supportive afterthought to a core component of multidisciplinary cancer care, supported by advances in formulation science, care delivery models, and evidence generation. Clinicians are increasingly adopting proactive nutritional screening and tailored interventions across enteral, oral, and parenteral modalities, which in turn is influencing procurement, distribution, and commercialization strategies. The interplay between clinical specificity, distribution pathways, and regional healthcare structures necessitates adaptive approaches that prioritize evidence-based adoption and operational continuity.

Stakeholders who succeed will be those that align clinical utility with pragmatic implementation: developing formulations that address patient-specific needs, building evidence that resonates with clinicians and payers, and maintaining supply chains that can respond to policy and logistical shifts. By integrating these elements, healthcare organizations and industry partners can enhance treatment tolerance, support recovery, and improve the overall patient experience within oncology care pathways. Moving forward, continued collaboration between clinical teams, manufacturers, and distribution partners will be essential to translate nutritional science into measurable improvements in patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology Nutrition Market, by Product Type

  • 8.1. Enteral Nutrition
    • 8.1.1. Elemental Formulas
    • 8.1.2. Modular Formulas
    • 8.1.3. Standard Formulas
  • 8.2. Oral Nutritional Supplements
    • 8.2.1. Disease Specific
    • 8.2.2. High Protein
    • 8.2.3. Immunonutrition
  • 8.3. Parenteral Nutrition
    • 8.3.1. Supplemental Parenteral Nutrition
    • 8.3.2. Total Parenteral Nutrition

9. Oncology Nutrition Market, by Route Of Administration

  • 9.1. Enteral
  • 9.2. Oral
  • 9.3. Parenteral

10. Oncology Nutrition Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Retail
  • 10.3. Retail Pharmacies
  • 10.4. Specialty Clinics

11. Oncology Nutrition Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Oncology Nutrition Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Oncology Nutrition Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Oncology Nutrition Market

15. China Oncology Nutrition Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Ajinomoto Co., Inc.
  • 16.7. B. Braun Melsungen AG
  • 16.8. Baxter International Inc.
  • 16.9. Danone S.A.
  • 16.10. Fresenius SE & Co. KGaA
  • 16.11. Hormel Foods Corporation
  • 16.12. Koninklijke DSM N.V.
  • 16.13. Meiji Holdings Co., Ltd.
  • 16.14. Nestle S.A.
  • 16.15. Reckitt Benckiser Group plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY NUTRITION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONCOLOGY NUTRITION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES ONCOLOGY NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA ONCOLOGY NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ELEMENTAL FORMULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ELEMENTAL FORMULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ELEMENTAL FORMULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY MODULAR FORMULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY MODULAR FORMULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY MODULAR FORMULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY STANDARD FORMULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY STANDARD FORMULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY STANDARD FORMULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY HIGH PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY HIGH PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY HIGH PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY IMMUNONUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY IMMUNONUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY IMMUNONUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY SUPPLEMENTAL PARENTERAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY SUPPLEMENTAL PARENTERAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY SUPPLEMENTAL PARENTERAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY TOTAL PARENTERAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY TOTAL PARENTERAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY TOTAL PARENTERAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS ONCOLOGY NUTRITION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. GCC ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 130. GCC ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. GCC ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 132. GCC ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. GCC ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. G7 ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 151. G7 ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 152. G7 ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 153. G7 ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. G7 ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. NATO ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 158. NATO ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 159. NATO ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 160. NATO ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. NATO ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ONCOLOGY NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES ONCOLOGY NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA ONCOLOGY NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA ONCOLOGY NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA ONCOLOGY NUTRITION MARKET SIZE, BY ENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA ONCOLOGY NUTRITION MARKET SIZE, BY ORAL NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA ONCOLOGY NUTRITION MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA ONCOLOGY NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA ONCOLOGY NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)